Mohamad Hatahet, MD
Internal Medicine · Waterford, MINPI 1952364242
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $288,629 of the $352,447 with a category attached, or 81.9%. Novo Nordisk accounts for 89.4% of it on its own, with 27 other manufacturers making up the rest. Reporting peaked in 2019 at $79,451 and has fallen 75.1% since, to $19,776 in 2025. Among internal medicine clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 645 payments — averaging $546.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$315K
- Lilly USA, LLC$33K
- AstraZeneca$708
- E.r. Squibb & Sons, L.L.C.$533
- Sanofi$511
- Johnson & Johnson$247
- plus $2K from 22 others
What the payments were for
- Consulting fees$8,1652%
- Speaking & faculty fees$288,62982%
- Travel & lodging$38,76611%
- Food & beverage$16,8375%
- Education$510%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 424 | $315,168 |
| Lilly USA, LLC | 102 | $33,024 |
| AstraZeneca | 22 | $708 |
| E.r. Squibb & Sons, L.L.C. | 11 | $533 |
| Sanofi | 5 | $511 |
| Johnson & Johnson | 7 | $247 |
| Regeneron Healthcare Solutions, Inc. | 2 | $244 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $234 |
| Pfizer | 8 | $226 |
| Currax Pharmaceuticals LLC | 21 | $210 |
| Merck | 6 | $171 |
| Redhill Biopharma Inc. | 1 | $122 |
| Boston Scientific | 1 | $120 |
| Bayer | 1 | $110 |
| AbbVie | 1 | $109 |
| Boehringer Ingelheim | 6 | $104 |
| Actelion Pharmaceuticals US, Inc. | 1 | $95 |
| Dynavax Technologies Corporation | 1 | $87 |
| GSK | 6 | $82 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $78 |
| Intra-sana Laboratories | 1 | $67 |
| Eisai Inc. | 4 | $58 |
| Novartis | 2 | $45 |
| Nalpropion Pharmaceuticals LLC | 2 | $31 |
| Sanofi-aventis U.S. LLC | 1 | $22 |
| Recor Medical Inc | 1 | $17 |
| Vivus LLC | 1 | $14 |
| Dexcom, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$352,447 in reported general payments places this provider in the 95th percentile of 4,567 internal medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 113 | $131,184 |
| RybelsusSemaglutide | 27 | $43,908 |
| JardianceEmpagliflozin | 29 | $36,089 |
| WegovySemaglutide | 27 | $34,908 |
| TrulicityDulaglutide | 22 | $30,134 |
| FarxigaDapagliflozin Propanediol | 28 | $23,278 |
| MounjaroTirzepatide | 19 | $22,441 |
| Ondansetron OdtOndansetron | 29 | $746 |
| Metformin Hcl | 61 | $504 |
| Atorvastatin Calcium | 25 | $423 |
| Levothyroxine Sodium | 30 | $272 |
| Pravastatin Sodium | 11 | $106 |
| Lisinopril | 14 | $100 |
| Amlodipine Besylate | 15 | $78 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Wegovy | $315,168 | $210,000167 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $33,024 | $52,57541 claims |
| Boehringer IngelheimJardiance | $104 | $36,08929 claims |
| AstraZenecaFarxiga | $708 | $23,27828 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,567 internal medicine providers in Michigan.
Other internal medicine in Waterford
- Terry SmithAnn Arbor$2.3M
- Michael ValituttoKalamazoo$1.8M
- Ulka VaishampayanAnn Arbor$996K
- Tina AbrahamPontiac$834K
- Steven KatzmanLivonia$715K
- Adam FormanSouthfield$453K
- Saroj NeupaneDetroit$373K
- James BazziDearborn Heights$368K
- A FendrickAnn Arbor$347K
- David StocktonDetroit$306K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.